Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Shelby Ernest

Nurse Practitioner, Family Fargo, ND Nurse Practitioner

NPI 1962998096 CMS profile 11068895

5049 33Rd Ave S, Fargo, ND 58102

Open in the dashboard

General payments

$4,100

216 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shelby Ernest of Fargo, ND is reported in the CMS Open Payments database as having received $4,100 across 216 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,024 72
2024 General $1,704 87
2023 General $949 45
2022 General $310 7
2021 General $114 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shelby Ernest
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Shelby Ernest were reported at $1,024. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Shelby Ernest Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $114 $124 $35–$379 $132
2022 $310 $141 $44–$430 $149
2023 $949 $154 $49–$476 $160
2024 $1,704 $165 $51–$504 $164
2025 $1,024 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,386 90 payments
  2. Phathom Pharmaceuticals, Inc. $430 16 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $392 28 payments
  4. E.R. Squibb & Sons, L.L.C. $267 3 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $267 15 payments
  6. Gilead Sciences, Inc. $187 5 payments
  7. Celltrion USA Inc. $185 10 payments
  8. Ardelyx, Inc. $150 5 payments
  9. QOL Medical, LLC $149 8 payments
  10. Madrigal Pharmaceuticals $99 4 payments
  11. Other $588 32 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,787 212 payments
  2. Education $313 4 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $887 65 payments
  2. STELARA $768 32 payments
  3. XIFAXAN $649 44 payments
  4. VOQUEZNA $325 9 payments
  5. ZEPOSIA $301 5 payments
  6. ENTYVIO $246 14 payments
  7. VEGZELMA $185 10 payments
  8. SIMPONI ARIA $164 12 payments
  9. SIMPONI $164 12 payments
  10. IBSRELA $150 5 payments
  11. Other $1,227 65 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

346

Median for Nurse Practitioner: 389

Drug cost

$39,989

Median for Nurse Practitioner: $21,885

Branded share of claims

36.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Linzess Linaclotide Brand 30 $18,521
Voquezna Vonoprazan Fumarate Brand 17 $10,662
Dexlansoprazole Dr Dexlansoprazole Brand 24 $3,543
Budesonide Dr Budesonide Brand 27 $2,381
Cholestyramine Cholestyramine (With Sugar) Brand 29 $1,942
Lactulose Generic 17 $582
Spironolactone Generic 18 $563
Nortriptyline Hcl Generic 60 $520
Pantoprazole Sodium Generic 47 $514
Omeprazole Generic 55 $458

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$223,959

Of which drugs: $200,624

Medicare patients

179

Average age 72

Services billed

29,931

122 women, 57 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 50%
Depression 31%
Diabetes 28%
Ischemic heart disease 26%
Osteoporosis 24%
Chronic kidney disease 21%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, ferric carboxymaltose, 1 mg J1439 Office 18 22,500 $18,306
Infusion, normal saline solution, 250 cc J7050 Office 11 46 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $359
$359 17 —
TREMFYA
  • Janssen Biotech, Inc. $262
$262 — —
STELARA
  • Janssen Biotech, Inc. $219
$219 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $217
$217 — —
ZEPOSIA
  • E.R. Squibb & Sons, L.L.C. $66
  • Celgene Corporation $16
$82 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

216 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in North Dakota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record